Loading
Latest filing published 27 May 2022 for Adamis Pharmaceuticals Corp.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Dennis J. Carlo PhD in Adamis Pharmaceuticals Corp, where the filings describe the role as chief executive. Between 6 March 2013 and 25 May 2022, the trades on record add up to 17 filings.
No open-market purchase appears, only 11 sales worth €128k. Other entries cover 3 share grants and 3 option exercises. Since January 2022: no purchases and 1 sale on the market.
Most recently, on 27 May 2022, the filings show an option exercise in Adamis Pharmaceuticals Corp. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations